190 related articles for article (PubMed ID: 16338952)
1. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.
Bernard-Pierrot I; Brams A; Dunois-Lardé C; Caillault A; Diez de Medina SG; Cappellen D; Graff G; Thiery JP; Chopin D; Ricol D; Radvanyi F
Carcinogenesis; 2006 Apr; 27(4):740-7. PubMed ID: 16338952
[TBL] [Abstract][Full Text] [Related]
2. Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(-4-hydroxybutyl)nitrosamine.
Dunois-Lardé C; Levrel O; Brams A; Thiery JP; Radvanyi F
Mol Carcinog; 2005 Mar; 42(3):142-9. PubMed ID: 15690367
[TBL] [Abstract][Full Text] [Related]
3. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
[TBL] [Abstract][Full Text] [Related]
4. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
[TBL] [Abstract][Full Text] [Related]
5. Frequent FGFR3 mutations in urothelial papilloma.
van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH
J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885
[TBL] [Abstract][Full Text] [Related]
6. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines.
Tomlinson DC; L'Hôte CG; Kennedy W; Pitt E; Knowles MA
Cancer Res; 2005 Nov; 65(22):10441-9. PubMed ID: 16288035
[TBL] [Abstract][Full Text] [Related]
7. No evidence of somatic FGFR3 mutation in various types of carcinoma.
Karoui M; Hofmann-Radvanyi H; Zimmermann U; Couvelard A; Degott C; Faridoni-Laurens L; Ahomadegbe JC; Gazzeri S; Brambilla E; Clerici T; Charbonnier P; Tresallet C; Mitry E; Penna C; Rougier P; Boileau C; Thiery JP; Nordlinger B; Franc B; Radvanyi F
Oncogene; 2001 Aug; 20(36):5059-61. PubMed ID: 11526491
[TBL] [Abstract][Full Text] [Related]
8. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans.
Logié A; Dunois-Lardé C; Rosty C; Levrel O; Blanche M; Ribeiro A; Gasc JM; Jorcano J; Werner S; Sastre-Garau X; Thiery JP; Radvanyi F
Hum Mol Genet; 2005 May; 14(9):1153-60. PubMed ID: 15772091
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.
Lindgren D; Liedberg F; Andersson A; Chebil G; Gudjonsson S; Borg A; Månsson W; Fioretos T; Höglund M
Oncogene; 2006 Apr; 25(18):2685-96. PubMed ID: 16532037
[TBL] [Abstract][Full Text] [Related]
10. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.
Kompier LC; van der Aa MN; Lurkin I; Vermeij M; Kirkels WJ; Bangma CH; van der Kwast TH; Zwarthoff EC
J Pathol; 2009 May; 218(1):104-12. PubMed ID: 19156776
[TBL] [Abstract][Full Text] [Related]
11. Comparable transforming capacities and differential gene expression patterns of variant FUS/CHOP fusion transcripts derived from soft tissue liposarcomas.
Schwarzbach MH; Koesters R; Germann A; Mechtersheimer G; Geisbill J; Winkler S; Niedergethmann M; Ridder R; Buechler MW; von Knebel Doeberitz M; Willeke F
Oncogene; 2004 Sep; 23(40):6798-805. PubMed ID: 15286712
[TBL] [Abstract][Full Text] [Related]
12. FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma.
Zhou H; He F; Mendelsohn CL; Tang MS; Huang C; Wu XR
Sci Rep; 2016 May; 6():25596. PubMed ID: 27157475
[TBL] [Abstract][Full Text] [Related]
13. Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix.
Wu R; Connolly D; Ngelangel C; Bosch FX; Muñoz N; Cho KR
Oncogene; 2000 Nov; 19(48):5543-6. PubMed ID: 11114733
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2.
Chaffer CL; Brennan JP; Slavin JL; Blick T; Thompson EW; Williams ED
Cancer Res; 2006 Dec; 66(23):11271-8. PubMed ID: 17145872
[TBL] [Abstract][Full Text] [Related]
15. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
Iyer G; Milowsky MI
Urol Oncol; 2013 Apr; 31(3):303-11. PubMed ID: 22285006
[TBL] [Abstract][Full Text] [Related]
17. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.
Billerey C; Chopin D; Aubriot-Lorton MH; Ricol D; Gil Diez de Medina S; Van Rhijn B; Bralet MP; Lefrere-Belda MA; Lahaye JB; Abbou CC; Bonaventure J; Zafrani ES; van der Kwast T; Thiery JP; Radvanyi F
Am J Pathol; 2001 Jun; 158(6):1955-9. PubMed ID: 11395371
[TBL] [Abstract][Full Text] [Related]
18. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.
Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M
Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607
[TBL] [Abstract][Full Text] [Related]
19. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.
di Martino E; L'Hôte CG; Kennedy W; Tomlinson DC; Knowles MA
Oncogene; 2009 Dec; 28(48):4306-16. PubMed ID: 19749790
[TBL] [Abstract][Full Text] [Related]
20. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.
Jebar AH; Hurst CD; Tomlinson DC; Johnston C; Taylor CF; Knowles MA
Oncogene; 2005 Aug; 24(33):5218-25. PubMed ID: 15897885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]